This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
BrainsWay’s Deep TMS therapy has been cleared by Europe’s CE certification for treating a variety of disorders:
Major Depressive Disorder (MDD)
Post-traumatic Stress Disorder (PTSD)
Schizophrenia (negative symptoms)
Obsessive Compulsive Disorder (OCD)
BrainsWay has also been cleared by the FDA for treatment resistant Major Depressive Disorder (MDD) and Obsessive Compulsive Disorder (OCD).